Parkinson's Disease Treatment Overview
24 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the primary role of MAO-B inhibitors in the treatment of Parkinson's disease?

  • To reduce acetylcholine levels
  • To provide immediate relief of motor symptoms
  • To enhance the effects of levodopa (correct)
  • To directly stimulate dopamine receptors
  • What effect does amantadine have on Parkinson's patients?

  • It enhances motor coordination
  • It decreases dyskinesias (correct)
  • It primarily increases dopamine production
  • It reduces tremors significantly
  • Which of the following best describes the effect of dopamine agonists in managing Parkinson's symptoms?

  • They mimic the effects of acetylcholine.
  • They are less effective than levodopa but can be used as an adjuvant therapy. (correct)
  • They act as a first-line treatment for all patients.
  • They solely target motor fluctuations.
  • Which non-pharmacological treatment has been shown to be more effective for reducing falls in Parkinson's disease patients?

    <p>Tai chi</p> Signup and view all the answers

    What is the primary factor that limits the use of delayed-release levodopa in Parkinson's disease treatment?

    <p>It should not be the drug of first choice.</p> Signup and view all the answers

    In patients treated with antipsychotic drugs, which medication is typically used to alleviate parkinsonian symptoms?

    <p>Benztropine</p> Signup and view all the answers

    Why is physical therapy considered to have only a modest benefit for Parkinson's disease patients?

    <p>It is generally not tailored to individual needs.</p> Signup and view all the answers

    What is a known adverse drug reaction of acetylcholine antagonists like Benztropine?

    <p>Dry mouth</p> Signup and view all the answers

    What is the primary action of MAO-B inhibitors in the treatment of Parkinson’s disease?

    <p>Reducing the degradation of dopamine</p> Signup and view all the answers

    Which of the following is NOT a role of dopamine agonists in managing Parkinson’s symptoms?

    <p>Enhancing the metabolism of levodopa</p> Signup and view all the answers

    How does Amantadine contribute to the management of Parkinson's disease?

    <p>Increasing the release of dopamine from neurons</p> Signup and view all the answers

    Which symptom is primarily associated with dopamine deficiency in Parkinson’s disease?

    <p>Bradykinesia</p> Signup and view all the answers

    In the management of Parkinson’s disease, what is the purpose of combining levodopa with a DOPA-decarboxylase inhibitor?

    <p>To increase the amount of levodopa that reaches the brain</p> Signup and view all the answers

    What role does COMT inhibitor play in Parkinson's disease treatment?

    <p>To prolong the action of levodopa</p> Signup and view all the answers

    Which of the following is considered a non-pharmacological treatment for Parkinson’s disease?

    <p>Deep brain stimulation</p> Signup and view all the answers

    What is a potential long-term consequence of using levodopa in Parkinson's disease patients?

    <p>Gradual decline in treatment effectiveness over time</p> Signup and view all the answers

    What is a common adverse drug reaction associated with Selegiline when used as an adjunct to levodopa?

    <p>Excitement, anxiety, and insomnia</p> Signup and view all the answers

    Which of the following best describes the mechanism of action of Amantadine?

    <p>Releases dopamine, inhibits amine uptake, or acts directly on dopamine receptors</p> Signup and view all the answers

    What is a key characteristic of the dopamine agonists Pramipexole and Ropinirole compared to other treatments?

    <p>They are selective for D1 and D2 receptors and show less fluctuation in effects</p> Signup and view all the answers

    Among the following options, which one is primarily used to manage the 'off effect' in Parkinson's patients?

    <p>Apomorphine</p> Signup and view all the answers

    What is a major limitation of using levodopa in advanced Parkinson's disease?

    <p>The duration of its clinical effect shortens as the disease progresses</p> Signup and view all the answers

    What is the recommended approach to mitigate the rapid fluctuations seen with levodopa treatment?

    <p>Use sustained-release preparations or co-administer with COMT inhibitors</p> Signup and view all the answers

    Which of the following side effects is least likely to occur with the use of dopamine agonists?

    <p>Rapid heartbeat</p> Signup and view all the answers

    In the context of Parkinson's treatment, Rasagiline is primarily used for what purpose?

    <p>To retard the progression of the disease</p> Signup and view all the answers

    Study Notes

    Parkinson's Disease Treatment

    • Levodopa is the first-line treatment for Parkinson's disease.
      • It is a metabolic precursor of dopamine.
      • Levodopa is rapidly decarboxylated by the enzyme DOPA-DECARBOXYLASE, converted to dopamine in extracerebral tissues.
      • Only a small amount of intact levodopa reaches the CNS and is converted to dopamine in the brain.
      • Levodopa is administered with a Dopa-decarboxilase inhibitor (Carbidopa or Benzeraside).
    • Levodopa's plasma half-life is short (about 2 hours).
      • Oral and subcutaneous slow release preparations have been developed.
    • Levodopa's therapeutic effectiveness:
      • Approximately 80% of patients show initial improvement with levodopa, particularly in rigidity and bradykinesia.
      • 20% are restored virtually to normal motor function.
      • Over time, the effectiveness of levodopa gradually declines.
      • Levodopa increases the life expectancy of PD patients, likely due to improved motor function.
    • Levodopa ADRs:
      • Involuntary movements (dyskinesia) due to short-acting levodopa: fluctuating plasma concentrations affect the face and limbs.
      • Longer-acting dopamine agonists are less problematic.
      • Nausea and anorexia.
      • Postural hypotension.
      • Psychological effects:
        • Schizophrenia-like syndrome with hallucinations.
        • 20% of patients: it causes confusion, disorientation, insomnia or nightmares.
    • Levodopa Fluctuations in Clinical State:
      • The "off effect" is a sudden worsening of motor symptoms in Parkinson's patients, where they may feel like they're stuck or unable to move.
        • This can be distressing and interfere with daily activities.
      • The more advanced Parkinson's disease, the shorter the clinical effect.
    • Levodopa Solutions to Fluctuations:
      • Using sustained-release preparations, or co-administration of COMT inhibitors such as Entacapone.
    • Dopamine agonists (Pramipexole, Ropinirole, Rotigotine, Apomorphine):
      • Pramipexole and Ropinirole are D1,2 selective, better tolerated, and do not show fluctuations.
      • Can cause somnolence, hallucinations, and compulsive behaviors.
      • Have a short plasma half-life (6–8 hours).
      • Three-times daily dosage is typically required.
      • Slow-release, once-daily formulations are now available.
      • Rotigotine is a newer agent, delivered as a transdermal patch.
      • Apomorphine (injection) may be used to control the ‘off effect’ with levodopa.
      • Apomorphine must be combined with an oral antiemetic drug.
      • Apomorphine is a last choice if other drugs fail.
    • MAO-B Inhibitors (Selegiline, Rasagiline):
      • Selegiline:
        • Selective and irreversible.
        • Used as an adjunct to levodopa.
        • ADRs: excitement, anxiety and insomnia.
      • Rasagiline:
        • Selective and irreversible.
        • May retard the progression of the disease.
      • Safinamide is undergoing clinical trials.
    • Other Drugs Used in Parkinson's Disease:
      • Amantadine:
        • Mechanism unknown, believed to release dopamine, inhibit amine uptake, or have a direct action on dopamine receptors.
      • Acetylcholine antagonists (Benztropine):
        • Muscarinic antagonists compensate for a lack of Dopamine.
        • Rarely used, except to treat parkinsonian symptoms in patients receiving antipsychotic drugs.
        • ADRs: dry mouth, constipation, impaired vision, urinary retention.
      • NMDA receptor blockers:
        • May be a novel therapeutic target.
        • Less effective than levodopa, but can be effective in reducing dyskinesias.
    • Treatment of Non-Motor Symptoms:
      • For depression, management should be tailored to individual needs.
      • Low frequency repetitive transcranial magnetic stimulation (rTMS) may improve motor system function in patients with Parkinson's disease.
      • Deep brain stimulation may be beneficial.
      • Physical therapy, exercise, and stretching can provide modest benefit.
      • Home-based balance and strengthening exercises programs can reduce the risk of falls in patients with less severe Parkinson's disease, but may not be effective in patients with high disease severity.
      • Tai Chi is more effective than stretching or resistance training for reducing falls in patients with Parkinson's disease.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    Description

    This quiz explores the treatment of Parkinson's disease, focusing on Levodopa as the first-line therapy. Understand its metabolic role, administration methods, and therapeutic effectiveness over time. Test your knowledge about how Levodopa impacts patients' motor functions and overall life expectancy.

    More Like This

    Parkinson’s Disease Treatment Basics
    19 questions
    Parkinson's Disease Treatment Overview
    37 questions
    Levodopa Treatment Insights
    93 questions

    Levodopa Treatment Insights

    FormidablePennywhistle avatar
    FormidablePennywhistle
    Use Quizgecko on...
    Browser
    Browser